|
IPC to partner with SEARN countries to share knowledge of India-specific ADR data for drug safety
|
|
Shardul Nautiyal, Mumbai
January 19 , 2019
|
|
|
Following Indian Pharmacopoeia Commission (IPC)'s collaboration with
Sweden-based Uppsala Monitoring Centre (UMC) to gather, collate and
analyse India-specific adverse drug reaction (ADR) data, IPC will now
partner with South East Asia Regulatory Network (SEARN) nation countries
to to share the knowledge of India specific ADR data for drug safety.
This will be done by analysing and utilising ADR data with the help of tools and systems available with Sweden-based UMC.
According
to Scientific director of IPC Dr G N Singh, “There is a need to educate
SEARN nation countries with pharmacovigilance activities towards drug
safety as IPC has also been designated as the WHO collaborative centre
for PV in public health. Our plan is to share benefits of India specific
ADR data, techniques and practices with the public health programmes of
SEARN nations through a harmonised approach.”
It has been
envisaged that the Central Drugs Standard Control Authority (CDSCO) of
India which is also a member of SEARN will help member countries like
Bangladesh, Bhutan, Korea, Indonesia, Maldives, Myanmar, Nepal, Sri
Lanka, Thailand and Timor to build capacity and enable National
Regulatory Authorities of respective nations to fulfill their mandates
and safeguard public health.
In this regard, a common
questionnaire in pharmacovigilance (PV) and Public Health has also been
framed for the SEARN countries to better understand their programmes.
This would help India to provide necessary support for developing and
integrating PV programmes in their public health systems.
CDSCO
under the Union health ministry had initiated a nation-wide
Pharmacovigilance Programme of India (PvPI) in July 2010 with Ghaziabad
based IPC as the national co-ordinating centre (NCC).
This
initiative is very much relevant as many of the medicines used in public
health programmes are new and have safety concerns associated with
them. This includes collaboration with WHO and others on the
establishment and training of a pharmacovigilance field force to
actively assemble case information from the programme treatment centres.
There
are 7 WHO collaborative centres globally in pharmacovigilance and WHO
collaborative centre for PV in public health and regulatory services
from India will serve as the 8th centre.
|
|
|
|
|
|
|
|
TOPICS
|
That foods might provide therapeutic benefits is clearly not a new concept. ...
|
|
|
|
|